Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 16, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
The filing reports an increase in the interest of Dr. R G Greig in Ordinary Share ADRs. This increase resulted from the re-investment of the dividend paid to shareholders on April 12, 2007, at a price of $56.83 per ADR. The specific quantity of shares acquired is listed as 48.63.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a compliance notification pursuant to Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 16, 2007
- Transaction Type: Re-investment of dividend into Ordinary Share ADRs
- Price per ADR: $56.83
- Individual Involved: Dr. R G Greig
- Dividend Payment Date: April 12, 2007